2015 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗浙江省专家共识(2015版)

2016-07-30 中国肿瘤科相关专家小组(统称) 中国普通外科杂志.2016,25(7):944-946.

热消融作为肿瘤的治疗方法之一已经广泛应用于肝癌等领域。然而国内外对于其在甲状腺结节的临床应用中仍然有很大的分歧。韩国放射协会和意大利专家分别在2012 年和2015 年发表了甲状腺结节的热消融治疗共识。而目前国内甲状腺的热消融处于起步阶段,发展极为迅猛,但在繁荣的背后乱象丛生,缺乏严格的指证把握。为严格规范热销融技术在甲状腺肿瘤中的应用,浙江省抗癌协会甲状腺肿瘤专业委员会多次组织相关专业的专家进行

中文标题:

2015 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗浙江省专家共识(2015版)

发布日期:

2016-07-30

简要介绍:

近年来,甲状腺良性结节、甲状腺微小癌的发病率呈逐年上升趋势。外科手术治疗依然是目前治疗上述疾病的首选且最明确有效的治疗方法。借助影像技术引导的热消融(射频、微波、激光)治疗具有损伤小、恢复较快、重复性较好且多数不影响美观等特点,近年来在部分甲状腺良性结节、部分低危甲状腺微小乳头状癌及颈部转移性淋巴结非外科手术治疗中已有所开展。 

为了尽可能规范上述疾病的微创热消融临床治疗,在严格遵循医学伦理和诊治原则前提下开展探讨性研究,积累循证医学证据,经多学科反复讨论,拟定本专家共识。 

1.甲状腺良性结节

适应证 需同时满足 1~2 项并满足第 3 项之一者。

⑴ 超声提示良性,FNA 证实良性结节;

⑵ 经评估,患者自身条件不能耐受外科手术治疗或患者主观意愿拒绝外科手术治疗的;

⑶ 同时需满足以下条件之一:

1) 自主功能性结节引起甲亢症状的;

2) 患者思想顾虑过重影响正常生活且拒绝临床观察(患者要求微创介入治疗);

3) 患者存在与结节明显相关的自觉症状(如:异物感、颈部不适或疼痛等)或影响美观,要求治疗的。 

禁忌证 符合下列任意一条即排除。

⑴ 巨大胸骨后甲状腺肿或大部分甲状腺结节位于胸骨后方(相对禁忌,分次消融可考虑);⑵ 甲状腺结节内存在粗大钙化灶;

⑶ 病灶对侧声带功能不正常;

⑷ 严重凝血机制障碍;

⑸ 严重心肺疾病。 

2 甲状腺微小癌 

适应证 需同时满足以下 3 项。

⑴ 超声提示单发结节,直径≤ 1 cm,没有贴近包膜(距离>2 mm),FNA 证实为乳头状癌,颈部没有可疑淋巴结转移;

⑵ 经评估,患者自身条件不能耐受外科手术治疗或患者主观拒绝外科手术治疗的;

⑶ 患者思想顾虑过重影响正常生活且拒绝临床观察(患者要求微创介入治疗)。 

禁忌证 符合下列任意一条即排除。

⑴ 颈部发现可疑转移性淋巴结,并经穿刺证实;

⑵ 甲状腺微小癌内存在粗大钙化灶;

⑶ 病灶对侧声带功能不正常;

⑷ 严重凝血机制障碍;

⑸ 严重心肺疾病。 

3 颈部转移性淋巴结 

适应证 颈部转移性淋巴结需同时满足以下条件:

⑴ 影像学提示转移性考虑,FNA 证实转移性淋巴结;

⑵ 行规范的根治性手术后,颈部淋巴结复发转移的,或甲状腺癌根治术后颈部复发转移性淋巴结行放射性碘治疗无效或拒绝行放射性碘治疗的;

⑶ 经评估,患者存在手术困难且自身条件不能耐受外科手术或患者主观意愿拒绝外科手术治疗的;

⑷ II-VI 区淋巴结,每个颈部分区内转移性淋巴结数目不超过 1 枚,且颈部转移性淋巴结总数量不超过 3 枚;

⑸ 淋巴结最大长径不超过 2 cm;转移性淋巴结能够与大血管、重要神经分离且有足够安全的操作空间。 

禁忌证 符合下列任意一条即排除。

⑴ 转移性淋巴结内存在粗大钙化或液化坏死;

⑵ 病灶位于Ⅵ区的转移性淋巴结,其病灶对侧声带功能不正常;

⑶ 严重凝血机制障碍;

⑷ 严重心肺疾病。

4 注意事项:

⑴ 需消融治疗的病灶术前需明确病理诊断或有相应可靠的影像学诊断支持;

⑵ 如患者在热消融过程中不能忍受疼痛或有明显不适,应减小消融功率或暂停消融;

⑶ 注射隔离液及穿刺操作的过程中需谨慎,避免损伤颈部血管、神经等;

⑷ 术中需监护并密切观察患者的心率、血压、呼吸、血氧饱和度等生命体征;

⑸ 术后 6 h 内禁食,并密切监护心率、血压、呼吸、血氧饱和度等生命体征;

⑹ 部分患者术后可出现轻度疼痛、发热(<39 ℃)、血肿及神经损伤等,应术前向患者及其家属交代;

⑺ 少部分患者有发生声音嘶哑的可能,这当中大多数可在 3 个月内自行恢复,应术前向患者及其家属交代;

⑻ 因肿瘤较大或其它因素,部分患者可能存在消融不完全,可能需要多次或分次消融,部分患者甚至需要中转开放性手术,这些均应术前向患者及其家属交代;

⑼ 由于肿瘤的特殊性,消融后仍存在肿瘤复发增大的可能,术后需定期复查随访,这些也应术前向患者及其家属交代。

制定者: 
浙江省抗癌协会甲状腺肿瘤专业委员会 
中国肿瘤科相关专家小组(统称)

拓展指南:与热消融相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2015 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗浙江省专家共识(2015版))] GetToolGuiderByIdResponse(projectId=1, id=788cc1c0012556e3, title=2015 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗浙江省专家共识(2015版), enTitle=, guiderFrom=中国普通外科杂志.2016,25(7):944-946., authorId=null, author=, summary=热消融作为肿瘤的治疗方法之一已经广泛应用于肝癌等领域。然而国内外对于其在甲状腺结节的临床应用中仍然有很大的分歧。韩国放射协会和意大利专家分别在2012 年和2015 年发表了甲状腺结节的热消融治疗共识。而目前国内甲状腺的热消融处于起步阶段,发展极为迅猛,但在繁荣的背后乱象丛生,缺乏严格的指证把握。为严格规范热销融技术在甲状腺肿瘤中的应用,浙江省抗癌协会甲状腺肿瘤专业委员会多次组织相关专业的专家进行, cover=, journalId=null, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sat Jul 30 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=<div><p class="MsoNormal">近年来,甲状腺良性结节、甲状腺微小癌的发病率呈逐年上升趋势。外科手术治疗依然是目前治疗上述疾病的首选且最明确有效的治疗方法。借助影像技术引导的热消融(射频、微波、激光)治疗具有损伤小、恢复较快、重复性较好且多数不影响美观等特点,近年来在部分甲状腺良性结节、部分低危甲状腺微小乳头状癌及颈部转移性淋巴结非外科手术治疗中已有所开展。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal">为了尽可能规范上述疾病的微创热消融临床治疗,在严格遵循医学伦理和诊治原则前提下开展探讨性研究,积累循证医学证据,经多学科反复讨论,拟定本专家共识。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal"><span style="font-weight: bold;">1.甲状腺良性结节</span></p><p class="MsoNormal"><span style="font-weight: bold;">适应证</span> 需同时满足 1~2 项并满足第 3 项之一者。<o:p></o:p></p><p class="MsoNormal">⑴ 超声提示良性,FNA 证实良性结节; <o:p></o:p></p><p class="MsoNormal">⑵ 经评估,患者自身条件不能耐受外科手术治疗或患者主观意愿拒绝外科手术治疗的;<o:p></o:p></p><p class="MsoNormal">⑶ 同时需满足以下条件之一:<o:p></o:p></p><p class="MsoNormal"><!--[if !supportLists]-->1) <!--[endif]-->自主功能性结节引起甲亢症状的;<o:p></o:p></p><p class="MsoNormal"><!--[if !supportLists]-->2) <!--[endif]-->患者思想顾虑过重影响正常生活且拒绝临床观察(患者要求微创介入治疗);<o:p></o:p></p><p class="MsoNormal">3) 患者存在与结节明显相关的自觉症状(如:异物感、颈部不适或疼痛等)或影响美观,要求治疗的。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal"><span style="font-weight: bold;">禁忌证</span> 符合下列任意一条即排除。<o:p></o:p></p><p class="MsoNormal">⑴ 巨大胸骨后甲状腺肿或大部分甲状腺结节位于胸骨后方(相对禁忌,分次消融可考虑);⑵ 甲状腺结节内存在粗大钙化灶;<o:p></o:p></p><p class="MsoNormal">⑶ 病灶对侧声带功能不正常;<o:p></o:p></p><p class="MsoNormal">⑷ 严重凝血机制障碍;<o:p></o:p></p><p class="MsoNormal">⑸ 严重心肺疾病。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal"><span style="font-weight: bold;">2 甲状腺微小癌<span style="font-size: 9pt;"> </span></span></p><p class="MsoNormal"><span style="font-weight: bold;">适应证</span> 需同时满足以下 3 项。<o:p></o:p></p><p class="MsoNormal">⑴ 超声提示单发结节,直径≤ 1 cm,没有贴近包膜(距离>2 mm),FNA 证实为乳头状癌,颈部没有可疑淋巴结转移;<o:p></o:p></p><p class="MsoNormal">⑵ 经评估,患者自身条件不能耐受外科手术治疗或患者主观拒绝外科手术治疗的;<o:p></o:p></p><p class="MsoNormal">⑶ 患者思想顾虑过重影响正常生活且拒绝临床观察(患者要求微创介入治疗)。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal"><span style="font-weight: bold;">禁忌证</span> 符合下列任意一条即排除。<o:p></o:p></p><p class="MsoNormal">⑴ 颈部发现可疑转移性淋巴结,并经穿刺证实;<o:p></o:p></p><p class="MsoNormal">⑵ 甲状腺微小癌内存在粗大钙化灶;<o:p></o:p></p><p class="MsoNormal">⑶ 病灶对侧声带功能不正常;<o:p></o:p></p><p class="MsoNormal">⑷ 严重凝血机制障碍;<o:p></o:p></p><p class="MsoNormal">⑸ 严重心肺疾病。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal"><span style="font-weight: bold;">3 颈部转移性淋巴结<span style="font-size: 9pt;"> </span></span></p><p class="MsoNormal"><span style="font-weight: bold;">适应证</span> 颈部转移性淋巴结需同时满足以下条件:<o:p></o:p></p><p class="MsoNormal">⑴ 影像学提示转移性考虑,FNA 证实转移性淋巴结;<o:p></o:p></p><p class="MsoNormal">⑵ 行规范的根治性手术后,颈部淋巴结复发转移的,或甲状腺癌根治术后颈部复发转移性淋巴结行放射性碘治疗无效或拒绝行放射性碘治疗的;<o:p></o:p></p><p class="MsoNormal">⑶ 经评估,患者存在手术困难且自身条件不能耐受外科手术或患者主观意愿拒绝外科手术治疗的;<o:p></o:p></p><p class="MsoNormal">⑷ II-VI 区淋巴结,每个颈部分区内转移性淋巴结数目不超过 1 枚,且颈部转移性淋巴结总数量不超过 3 枚;<o:p></o:p></p><p class="MsoNormal">⑸ 淋巴结最大长径不超过 2 cm;转移性淋巴结能够与大血管、重要神经分离且有足够安全的操作空间。<span style="font-size: 9pt;"> </span></p><p class="MsoNormal"><span style="font-weight: bold;">禁忌证</span> 符合下列任意一条即排除。<o:p></o:p></p><p class="MsoNormal">⑴ 转移性淋巴结内存在粗大钙化或液化坏死;<o:p></o:p></p><p class="MsoNormal">⑵ 病灶位于Ⅵ区的转移性淋巴结,其病灶对侧声带功能不正常;<o:p></o:p></p><p class="MsoNormal">⑶ 严重凝血机制障碍;<o:p></o:p></p><p class="MsoNormal">⑷ 严重心肺疾病。<o:p></o:p></p><p class="MsoNormal"><span style="font-weight: bold;">4 注意事项:</span><o:p></o:p></p><p class="MsoNormal">⑴ 需消融治疗的病灶术前需明确病理诊断或有相应可靠的影像学诊断支持;<o:p></o:p></p><p class="MsoNormal">⑵ 如患者在热消融过程中不能忍受疼痛或有明显不适,应减小消融功率或暂停消融;<o:p></o:p></p><p class="MsoNormal">⑶ 注射隔离液及穿刺操作的过程中需谨慎,避免损伤颈部血管、神经等; <o:p></o:p></p><p class="MsoNormal">⑷ 术中需监护并密切观察患者的心率、血压、呼吸、血氧饱和度等生命体征;<o:p></o:p></p><p class="MsoNormal">⑸ 术后 6 h 内禁食,并密切监护心率、血压、呼吸、血氧饱和度等生命体征;<o:p></o:p></p><p class="MsoNormal">⑹ 部分患者术后可出现轻度疼痛、发热(<39 ℃)、血肿及神经损伤等,应术前向患者及其家属交代;<o:p></o:p></p><p class="MsoNormal">⑺ 少部分患者有发生声音嘶哑的可能,这当中大多数可在 3 个月内自行恢复,应术前向患者及其家属交代;<o:p></o:p></p><p class="MsoNormal">⑻ 因肿瘤较大或其它因素,部分患者可能存在消融不完全,可能需要多次或分次消融,部分患者甚至需要中转开放性手术,这些均应术前向患者及其家属交代;<o:p></o:p></p><p class="MsoNormal">⑼ 由于肿瘤的特殊性,消融后仍存在肿瘤复发增大的可能,术后需定期复查随访,这些也应术前向患者及其家属交代。<o:p></o:p></p> </div> <div><span style="font-weight: bold;">制定者: </span></div> <div>浙江省抗癌协会甲状腺肿瘤专业委员会 </div> <div>中国肿瘤科相关专家小组(统称)</div> <div><br> </div> 拓展指南:与热消融相关指南:<br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=d70b31c001069e56" title="热消融治疗原发性和转移性肺部肿瘤的专家共识(2014年版)" target="_blank">热消融治疗原发性和转移性肺部肿瘤的专家共识(2014年版)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%83%AD%E6%B6%88%E8%9E%8D" target="_blank">有关热消融更多指南</a></ul>, tagList=[TagDto(tagId=37329, tagName=甲状腺良性结节), TagDto(tagId=37330, tagName=微小癌), TagDto(tagId=37331, tagName=颈部转移性淋巴结)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3387, appHits=229, showAppHits=0, pcHits=2429, showPcHits=1227, likes=154, shares=8, comments=6, approvalStatus=1, publishedTime=Tue Aug 16 12:14:40 CST 2016, publishedTimeString=2016-07-30, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Tue Aug 16 12:14:40 CST 2016, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 19:20:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2015 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗浙江省专家共识(2015版))])
2015 甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗浙江省专家共识(2015版)
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1009669, encodeId=cd931009669cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d6d4735526, createdName=31379099, createdTime=Fri Aug 20 10:35:49 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297383, encodeId=faaa29e38384, content=值得关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd782293422, createdName=121ef1c7m57(暂无昵称), createdTime=Sun Mar 18 10:43:47 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=100007, encodeId=d4c010000edc, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 21:38:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99840, encodeId=d1d89984042, content=值得收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:28:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99836, encodeId=a3e89983627, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:27:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2021-08-20 31379099

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1009669, encodeId=cd931009669cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d6d4735526, createdName=31379099, createdTime=Fri Aug 20 10:35:49 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297383, encodeId=faaa29e38384, content=值得关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd782293422, createdName=121ef1c7m57(暂无昵称), createdTime=Sun Mar 18 10:43:47 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=100007, encodeId=d4c010000edc, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 21:38:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99840, encodeId=d1d89984042, content=值得收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:28:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99836, encodeId=a3e89983627, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:27:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2018-03-18 121ef1c7m57(暂无昵称)

    值得关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1009669, encodeId=cd931009669cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d6d4735526, createdName=31379099, createdTime=Fri Aug 20 10:35:49 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297383, encodeId=faaa29e38384, content=值得关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd782293422, createdName=121ef1c7m57(暂无昵称), createdTime=Sun Mar 18 10:43:47 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=100007, encodeId=d4c010000edc, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 21:38:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99840, encodeId=d1d89984042, content=值得收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:28:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99836, encodeId=a3e89983627, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:27:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2016-08-17 doctorJiangchao

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1009669, encodeId=cd931009669cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d6d4735526, createdName=31379099, createdTime=Fri Aug 20 10:35:49 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297383, encodeId=faaa29e38384, content=值得关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd782293422, createdName=121ef1c7m57(暂无昵称), createdTime=Sun Mar 18 10:43:47 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=100007, encodeId=d4c010000edc, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 21:38:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99840, encodeId=d1d89984042, content=值得收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:28:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99836, encodeId=a3e89983627, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:27:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2016-08-17 doctorJiangchao

    值得收藏

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1009669, encodeId=cd931009669cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d6d4735526, createdName=31379099, createdTime=Fri Aug 20 10:35:49 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297383, encodeId=faaa29e38384, content=值得关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd782293422, createdName=121ef1c7m57(暂无昵称), createdTime=Sun Mar 18 10:43:47 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=100007, encodeId=d4c010000edc, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 21:38:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99840, encodeId=d1d89984042, content=值得收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:28:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99836, encodeId=a3e89983627, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:27:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2016-08-17 doctorJiangchao

    继续学习

    0